Research Areas
► government ethics and the regulation of health care (e.g., conflicts of interest, lobbying, revolving door, transparency)
► Food and Drug Administration (FDA)
► technologies (e.g., drugs, devices, AI, cybersecurity)
Metholodogical Approach
► guided by economic and sociological theory
► quantitative (statistical / econometric) methods
► large administrative, survey, and other datasets
Recent Activity
>> New Working Paper<<
April 2026
Profit regulation and strategic transfer pricing by vertically integrated firms: Evidence from health care. NBER Working Paper 35043.
>> New Publication<<
March 2026
Conflicts of interest in advisory committees — facts, fallacies, and the limits of reform. [PDF] [original ms] N Engl J Med 2026; 394:1150-1152.
>> New Working Paper<<
January 2026
“B” is for “big gifts”: Characterizing donor-recipient charitable relationships using Form 990 Schedule B. SSRN Working Paper.
STAT News
April 1, 2026
Government watchdog urges FDA to finalize guidance for advisory committee conflicts of interest [PDF]
by Ed Silverman
Bloomberg Law
March 17, 2026
Big Pharma gets win in RFK Jr vaccine pause, unsure if it lasts [PDF]
by Nyah Phengsitthy
STAT News
March 9, 2026
As controversial decisions mount, FDA shuns public advisory meetings [PDF]
by Lizzy Lawrence